 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
| «1234567 |
- | entecavir / Generic mfg., lamivudine HBV / Generic mfg., lamivudine / Generic mfg.
Enrollment open: Comparison of Prophylactic Antiviral Efficacy in Patients Undergoing Chemotherapy: Entecavir Versus Lamivudine (clinicaltrials.gov) - May 27, 2013
P3, N=180, Recruiting, Sponsor: Seoul National University Hospital
Not yet recruiting --> Recruiting
- lamivudine HBV / Generic mfg., lamivudine / Generic mfg., adefovir dipivoxil / Generic mfg.
Trial completion, Monotherapy: Study Comparing the Safety of Switching From Lamivudine to Adefovir Dipivoxil Versus Overlapping Lamivudine and Adefovir Before Adefovir Dipivoxil Monotherapy in Patients With Chronic Hepatitis B (clinicaltrials.gov) - May 7, 2013
P4, N=40, Completed, Sponsor: Thomas Jefferson University
Not yet recruiting --> Recruiting Recruiting --> Completed
- || lamivudine HBV / Generic mfg.
New P3 trial: HBSAE: Tenofovir Versus Lamivudine for Patients of Chronic Hepatitis B With Severe Acute Exacerbation (clinicaltrials.gov) - May 5, 2013
P3, N=120, Recruiting, Sponsor: Kaohsiung Veterans General Hospital.
- | Tyzeka (telbivudine) / Novartis
New P4 trial: TeSLA: Comparison of Telbivudine Plus Adefovir With Lamivudine Plus Adefovir for the Treatment of Lamivudine-resistant Chronic Hepatitis B at 52 Weeks: A Pilot Study (clinicaltrials.gov) - Mar 3, 2013
P4, N=60, Recruiting, Sponsor: Korea University
- |||| entecavir / Generic mfg., lamivudine HBV / Generic mfg., lamivudine / Generic mfg.
Enrollment open: Comparison Between Lamivudine and Entecavir Treatment in Spontaneous Severe Acute Exacerbation (clinicaltrials.gov) - Feb 17, 2013
P4, N=98, Recruiting, Sponsor: Taichung Veterans General Hospital
Recruiting --> Completed Not yet recruiting --> Recruiting
- ||||| Tyzeka (telbivudine) / Novartis
New P4 trial: Study of Telbivudine and Lamivudine to Prevent Vertical Transmission of Hepatitis B (clinicaltrials.gov) - Dec 4, 2012
P4, N=700, Completed, Sponsor: Beijing YouAn Hospital
- | lamivudine HBV / Generic mfg., adefovir dipivoxil / Generic mfg.
New P4 trial: TDF VS LAM + ADV in LAM + ADV Treated LAM-resistant CHB Patients With Undetectable Hepatitis B Virus DNA (clinicaltrials.gov) - Nov 20, 2012
P4, N=171, Enrolling by invitation, Sponsor: Keimyung University Dongsan Medical Center
- lamivudine HBV / Generic mfg., lamivudine / Generic mfg., adefovir dipivoxil / Generic mfg.
Trial initiation date: Switch to Tenofovir Versus Continue Lamivudine/Adefovir Treatment in Lamivudine-resistance Chronic Hepatitis B Patients (clinicaltrials.gov) - Nov 1, 2012
P4, N=160, Recruiting, Sponsor: Taipei Veterans General Hospital, Taiwan
Not yet recruiting --> Recruiting Initiation date: Dec 2011 --> Sep 2012
- lamivudine HBV / Generic mfg., lamivudine / Generic mfg., adefovir dipivoxil / Generic mfg.
Enrollment open: Switch to Tenofovir Versus Continue Lamivudine/Adefovir Treatment in Lamivudine-resistance Chronic Hepatitis B Patients (clinicaltrials.gov) - Nov 1, 2012
P4, N=160, Recruiting, Sponsor: Taipei Veterans General Hospital, Taiwan
Initiation date: Dec 2011 --> Sep 2012 Not yet recruiting --> Recruiting
- |||| Trial completion: Adding Adefovir Dipivoxil Versus Switching to Entecavir in Patients With Lamivudine-resistant Chronic Hepatitis B (clinicaltrials.gov) - Oct 17, 2012
P4, N=219, Completed, Sponsor: Korea University
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Trial completion: CAESAR: Entecavir Plus Adefovir in Lamivudine-Resistant Chronic Hepatitis B Patients Who Fail Lamivudine Plus Adefovir (clinicaltrials.gov) - Sep 25, 2012
P4, N=90, Completed, Sponsor: Asan Medical Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Enrollment change: Sex, Aging and Antiretroviral Pharmacokinetics (clinicaltrials.gov) - Sep 17, 2012
P=N/A, N=11, Completed, Sponsor: Kristine Patterson, MD
Active, not recruiting --> Completed N=42 --> 11
- Trial completion: Sex, Aging and Antiretroviral Pharmacokinetics (clinicaltrials.gov) - Sep 17, 2012
P=N/A, N=11, Completed, Sponsor: Kristine Patterson, MD
N=42 --> 11 Recruiting --> Completed
- |||| Levovir (clevudine) / Bukwang Pharma, Eisai
Trial completion: Switching Study From Lamivudine to Clevudine in the Chronic Hepatitis B Patients (clinicaltrials.gov) - Jul 23, 2012
P4, N=100, Completed, Sponsor: Bukwang Pharmaceutical
Recruiting --> Completed Recruiting --> Completed
- ||||||| Levovir (clevudine) / Bukwang Pharma, Eisai
Trial completion: Compare the Efficacy and Safety of 48-week Treatment With Clevudine 30mg Versus Lamivudine 100mg for CHB Infection (clinicaltrials.gov) - Jul 23, 2012
P3, N=92, Completed, Sponsor: Bukwang Pharmaceutical
Recruiting --> Completed Active, not recruiting --> Completed
- ||||| entecavir / Generic mfg., lamivudine HBV / Generic mfg., lamivudine / Generic mfg.
New P4 trial: Comparison Between Lamivudine and Entecavir Treatment in Spontaneous Severe Acute Exacerbation (clinicaltrials.gov) - Jun 21, 2012
P4, N=98, Recruiting, Sponsor: Taichung Veterans General Hospital
- | Tyzeka (telbivudine) / Novartis
New P4 trial: Antiviral Efficacy of Switching to ETV Plus TDF (clinicaltrials.gov) - May 13, 2012
P4, N=104, Active, not recruiting, Sponsor: Yonsei University
- entecavir / Generic mfg., lamivudine HBV / Generic mfg., lamivudine / Generic mfg.
Enrollment change: Continuing Lamivudine Versus Switching to Entecavir in Patients Who Achieved Undetectable HBV DNA (clinicaltrials.gov) - May 6, 2012
P4, N=72, Completed, Sponsor: Yonsei University
Active, not recruiting --> Completed N=200 --> 72
- entecavir / Generic mfg., lamivudine HBV / Generic mfg., lamivudine / Generic mfg.
Trial completion: Continuing Lamivudine vs Switching to Entecavir in Patients With Detectable HBV DNA (clinicaltrials.gov) - May 6, 2012
P4, N=72, Completed, Sponsor: Yonsei University
N=200 --> 72 Active, not recruiting --> Completed
- entecavir / Generic mfg., lamivudine HBV / Generic mfg., lamivudine / Generic mfg.
Trial completion: Continuing Lamivudine Versus Switching to Entecavir in Patients Who Achieved Undetectable HBV DNA (clinicaltrials.gov) - May 6, 2012
P4, N=72, Completed, Sponsor: Yonsei University
Active, not recruiting --> Completed Active, not recruiting --> Completed
- || entecavir / Generic mfg., lamivudine HBV / Generic mfg., lamivudine / Generic mfg.
New P3 trial: Comparison of Prophylactic Antiviral Efficacy in Patients Undergoing Chemotherapy: Entecavir Versus Lamivudine (clinicaltrials.gov) - Apr 16, 2012
P3, N=180, Recruiting, Sponsor: Seoul National University Hospital
- Tyzeka (telbivudine) / Novartis
Trial withdrawal: Treatment of Hepatitis B Virus (HBV) Before Beginning Anti-HIV Drugs in Patients With Both HBV and HIV (clinicaltrials.gov) - Apr 5, 2012
P=N/A, N=0, Withdrawn, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed Active, not recruiting --> Withdrawn
- Tyzeka (telbivudine) / Novartis
Enrollment change: Treatment of Hepatitis B Virus (HBV) Before Beginning Anti-HIV Drugs in Patients With Both HBV and HIV (clinicaltrials.gov) - Apr 5, 2012
P=N/A, N=0, Withdrawn, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Withdrawn N=36 --> 0
- Enrollment change: A Comparison of Adefovir and Tenofovir for the Treatment of Lamivudine-Resistant Hepatitis B Virus in People With HIV (clinicaltrials.gov) - Apr 5, 2012
P2, N=90, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
N=36 --> 0 N=53 --> 90
- | New P4 trial, Combination therapy: Adefovir and Lamivudine for Entecavir Resistance (ALTER Study) (clinicaltrials.gov) - Mar 5, 2012
P4, N=20, Completed, Sponsor: Korea University
- | lamivudine HBV / Generic mfg., lamivudine / Generic mfg., adefovir dipivoxil / Generic mfg.
New P4 trial: Switch to Tenofovir Versus Continue Lamivudine/Adefovir Treatment in Lamivudine-resistance Chronic Hepatitis B Patients (clinicaltrials.gov) - Dec 11, 2011
P4, N=160, Recruiting, Sponsor: Taipei Veterans General Hospital, Taiwan
- | lamivudine HBV / Generic mfg., adefovir dipivoxil / Generic mfg.
New P4 trial: CLINICAL TRIAL WITH TENOFOVIR VERSUS LAMIVUDINE PLUS ADEFOVIR DIPIVOXIL IN LAMIVUDINE-RESISTANT CHRONIC HEPATITIS-B PATIENTS WITH UNDETECTABLE VIRAL LOAD ENSAYO CL (EUDRACT) - Nov 2, 2011
P4, N=100, Ongoing, Sponsor: Manuel Rodr
- | lamivudine HBV / Generic mfg., lamivudine / Generic mfg.
New P2 trial: Efficacy and Safety of Dual-plasmid Hepatitis B Virus DNA Vaccine in Chronic Hepatitis B Patients (clinicaltrials.gov) - Sep 21, 2011
P2, N=240, Recruiting, Sponsor: Fuqiang Yang
- | Nabi-HB (hepatitis B immune globulin) / ADMA Biologics
New P1/2 trial, Combination therapy: Pilot Study to Assess the Pharmacokinetics of Intravenous Nabi 5% Hepatitis B Immune Globulin (Boca HBVIg) Used in Combination With Lamivudine for Patients With Hepatitis B Virus (HBV) Associated Liver Disease Undergoing Liver Transplantation (clinicaltrials.gov) - Aug 17, 2011
P1/2, N=30, Completed, Sponsor: Biotest Pharmaceuticals Corporation